RAD17

Across TCGA pan-cancer cohorts, RAD17 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RAD17’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where RAD17 RNA is repressed in tumor relative to normal tissue. In most cancer types RAD17 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, LIHC, and HNSC are the cancer types where RAD17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAD17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.584	<.001	10	view →
LIHC	Female	II,III,IV	+0.754	<.001	9	view →
HNSC	All	III,IV	+0.394	.003	8	view →
LUAD	Male	All	+0.443	<.001	5	view →
KICH	All	All	−0.610	<.001	4	view →
CHOL	All	All	+1.512	<.001	3	view →
KIRP	Male	All	−0.323	.010	2	view →
BRCA	All	III,IV	+0.261	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RAD17–THCA

Open the THCA breakdown →